小儿难治性支原体肺炎应用喹诺酮类进行治疗的研究

目的:探讨喹诺酮类药物治疗小儿难治性支原体肺炎的临床疗效。方法:选取我院2010年2月-2013年12月诊断为难治性支原体肺炎的患儿20例,随机平均分为两组,对照组使用阿奇霉素,治疗组使用左氧氟沙星,两组患儿均用其他抗生素,抗病毒、糖皮质激素及其他药物对症支持,观察两组患儿临床疗效、住院时间、肺CT等改变的情况,并进行比较。结果:治疗组患者发热、咳嗽、喘憋、干湿罗音等症状体征持续时间和平均住院天数等均较对照组明显缩短(P0.05),有统计学意义,治疗组总有效率为92.3%,高于对照组的80.0%,两组比较差异显著(P0.05),有统计学意义,治疗组患儿肺CT显示肺部病变好转的情况,CRP,血沉恢复正常的时间与对照组相比差异显著(P0.05),有统计学意义,且未发现明显的不良反应。结论:应用喹诺酮类药物治疗小儿难治性支原体肺炎的临床疗效显著,值得临床尝试。

The Treatment Research of Quinolone Using in Children Refractory Mycoplasma Pneumonia*

Objective： To explore the diagnosis and quinolones in the treatment of children with refractory mycoplasma pneumonia. Methods： Selecting 20 cases in children with refractory mycoplasma pneumonia who were in our hospital from February 2010 to Decem- ber 2013, and divided into two groups randomly. The patients of control group azithromycin while using levofloxacin in treatment group. At the moment, two groups of children were suited the support with other antibiotics, antiviral, glucocorticoidand other drugs. What＇s more, we have to observe the clinical curative effect, the length of time and lung CT changes of two groups, then take a comparison. Results： There is statistical significance between the control group and reatment group, while the reatment group was shorter significantly than control group with fever, coughing, wheezing suppress, dry and wet rale signs and symptoms such as duration and average hospital- ization days. The total effective rate of treatment group was 92.3%, which is higher than that of control group with 80.0%, while two groups are significant difference （P〈 0.05）, there is statistical significance. The treatment group with lung CT lung lesions were im- proved, CRP, blood sedimentation restore normal time significant difference compared with control group （P 〈 0.05）, there is statistical significance, and found no significant adverse reactions. Conclusion： The clinical curative effect of application of quinolones in the treat- ment of children with refractory mycoplasma pneumonia is distinct, and it＇s worthy of clinical experiment.